Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

2.80
-0.0300-1.06%
Post-market: 2.800.00000.00%19:56 EST
Volume:473.80K
Turnover:1.33M
Market Cap:180.52M
PE:-4.74
High:2.89
Open:2.82
Low:2.67
Close:2.83
52wk High:7.13
52wk Low:1.12
Shares:64.47M
Float Shares:44.93M
Volume Ratio:1.83
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5905
EPS(LYR):-0.7575
ROE:-3727.94%
ROA:-87.09%
PB:-1.44
PE(LYR):-3.70

Loading ...

Galectin Therapeutics Approves Retention Bonuses for Key Executives

TIPRANKS
·
Jan 22

Galectin Therapeutics Awards Retention Bonuses to Chief Medical and Financial Officers

Reuters
·
Jan 22

Top Galectin Therapeutics Insider Makes Notable Move With Company Stock

TIPRANKS
·
Jan 14

Marc Rubin Resigns from Galectin Therapeutics Board

Reuters
·
Jan 13

Galectin Therapeutics CFO Jack W. Callicutt Reports Disposal of Common Shares

Reuters
·
Jan 07

Galectin Therapeutics Chief Medical Officer Jamil Khurram Reports Disposal of Common Shares

Reuters
·
Jan 06

Galectin Therapeutics Director Kevin D. Freeman Reports Acquisition of Common Shares

Reuters
·
Dec 24, 2025

Galectin Therapeutics Chief Medical Officer Jamil Khurram Reports Disposal of Common Shares

Reuters
·
Dec 20, 2025

Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line

MT Newswires Live
·
Dec 19, 2025

BRIEF-Galectin Therapeutics Enters Line Of Credit Agreement

Reuters
·
Dec 19, 2025

BRIEF-Galectin Therapeutics Provides Regulatory Update Following FDA Written Response

Reuters
·
Dec 19, 2025

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit From Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027

THOMSON REUTERS
·
Dec 19, 2025

Galectin Therapeutics Inc - to Pursue Follow-up Type C Meeting

THOMSON REUTERS
·
Dec 19, 2025

Galectin Therapeutics Inc - Enters Line of Credit Agreement - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Galectin Therapeutics Secures Additional $10 Million Line of Credit from Richard E. Uihlein

Reuters
·
Dec 19, 2025

10X Fund, L.P. Reports Disposal of Galectin Therapeutics Inc. Common Shares

Reuters
·
Dec 18, 2025

Galectin Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 17, 2025

Director Harold H. Shlevin Reports Disposal of Galectin Therapeutics Inc. Common Shares

Reuters
·
Dec 17, 2025

Galectin Therapeutics Director Harold H. Shlevin Reports Disposal of Common Shares

Reuters
·
Dec 10, 2025

Galectin Therapeutics Inc. held annual shareholder meeting

Reuters
·
Dec 08, 2025